Community widely reports neuropsychiatric side effects (anxiety, panic, anhedonia) that barely appear in preclinical literature: animal models cannot self-report mood effects
While semaglutide produces significant results alone, combining it with structured behavioral changes appears to enhance outcomes
Insulin Sensitivity and Beta Cell Function Research revealed improvements in both insulin sensitivity and pancreatic function[13]: Enhanced HOMA-IR scores indicating improved insulin sensitivity Reduced fasting insulin levels despite improved glucose control Preserved or improved beta cell function markers (HOMA-beta, C-peptide) Potential protective effects on pancreatic beta cell mass in preclinical models Cardiovascular and Metabolic Health Research Lipid Profile Improvements Studies documented favorable effects on multiple cardiovascular risk markers[14]: LDL cholesterol reductions of 15-20% observed with GLP3 Triglyceride reductions of 20-30% documented across studies Improved HDL cholesterol levels in some study populations Potential PCSK9 degradation effects through glucagon receptor activation Blood Pressure and Heart Rate Effects Cardiovascular monitoring in clinical trials revealed consistent patterns[15]: Systolic blood pressure reductions of 5-10 mmHg observed with weight loss Diastolic pressure improvements of 3-5 mmHg documented Dose-dependent heart rate increases (5-10 bpm) that peaked at 24 weeks then declined Heart rate changes similar to other GLP-1 receptor agonists Hepatic Steatosis and Liver Health Research Liver Fat Reduction Studies Research in metabolic dysfunction-associated steatotic liver disease (MASLD) models showed remarkable effects[16]: GLP3 achieved 82% relative liver fat reduction after 48 weeks in phase 2a MASLD trials Over 85% of participants achieved resolution of MASLD (liver fat below 5%) Improvements in liver enzymes (ALT, AST) and fibrosis biomarkers documented Potential anti-fibrotic effects through multiple pathway modulation The glucagon receptor component appears particularly relevant for liver fat reduction, as the liver is rich in glucagon receptors but lacks GLP-1 receptors
and synephrine improve brown adipose tissue function in adolescent mice programmed by early postnatal overfeeding Andressa Cardoso Guimares, Egberto Gaspar de Moura, Stephanie Giannini Silva, Bruna Pereira Lopes, Iala Milene Bertasso, Carla Bruna Pietrobon, Fernanda Torres Quitete, Tayanne de Oliveira Malafaia, rica Patrcia Garcia Souza, Patrcia Cristina Lisboa, Frontiers in Nutrition.2024;[Epub] CrossRef Au@16-pH-16/miR-21 mimic nanosystem: An efficient treatment for obesity through browning and thermogenesis induction Said Lhamyani, Adriana-Mariel Gentile, Mara Mengual-Mesa, Elia Grueso, Rosa M
